Trust Signals
Key Takeaways
- Tesamorelin is the only research-peptide class compound with FDA approval for fat reduction, supported by two pivotal RCTs showing roughly 15 to 18 percent visceral fat loss in its approved indication (Falutz et al., NEJM 2007).
- AOD-9604 failed its human Phase IIb/III obesity trials; animal lipolysis data did not translate to human fat loss at doses studied.
- Semaglutide and liraglutide are GLP-1 peptides with full FDA obesity approval and the largest Phase III human datasets, making them categorically stronger than any research compound.
- CJC-1295 with DAC extends GH-stimulating half-life to roughly 6 to 8 days via albumin binding, but no large independent RCT has fat loss as a primary endpoint in healthy adults.
- A legitimate peptide COA requires mass spectrometry identity confirmation plus HPLC purity above 98%; a COA without MS is incomplete regardless of stated purity.
What Is the Best Fat Burning Peptide?
The best fat burning peptide depends entirely on the evidence standard you apply. For general obesity with the largest human RCT dataset, semaglutide wins outright. For visceral fat in a specific clinical population, tesamorelin holds FDA approval. For research compounds used off-label, CJC-1295 plus ipamorelin has the most clinical rationale, but no Phase III fat-loss data. AOD-9604 lost its human trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: All Major Peptides Graded
- How Fat-Burning Peptides Work: Mechanism with Numbers
- The Top Fat-Burning Peptides Ranked
- What Most Pages Get Wrong About Fat-Burning Peptides
- The Chemistry Behind Storage and Stability Rules
- Honest Head-to-Head: Peptides vs. Real Alternatives
- Operational and Label Literacy: How to Judge a Product
- Dosing Reference Table
- FAQ
- Sources
- Disclaimers
What Does the Evidence Actually Say? The Evidence Ledger
Every major claim about fat-burning peptides is graded below. Confidence ratings follow a four-level scale matching GRADE methodology.
| Peptide | Claimed Effect | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Semaglutide | Body weight and fat mass reduction in obesity | Multiple large Phase III RCTs (STEP program, n=4,500+ total) | Strong positive: avg ~15% body weight loss vs placebo at 68 weeks (STEP 1, Wilding et al., NEJM 2021) | High |
| Tesamorelin | Visceral fat reduction in HIV lipodystrophy | Phase III RCT (Falutz et al., NEJM 2007 and confirmatory trial) | Positive: ~15 to 18% visceral fat reduction vs placebo | High (in approved population) |
| Tesamorelin | Visceral fat in healthy, non-HIV adults | Small pilot studies only | Weakly positive, not confirmed | Low |
| CJC-1295 with DAC | Fat loss via sustained GH elevation | Small human PK/PD study (Teichman et al., J Clin Endocrinol Metab 2006) confirming GH rise; no fat-loss RCT | GH elevation confirmed; fat loss unproven as primary endpoint | Low |
| Ipamorelin | Fat loss via GH pulse amplification | Human trials for GI motility (not fat loss); animal fat data only for lipolysis endpoint | Mechanistically plausible; human fat-loss evidence absent | Very Low |
| AOD-9604 | Fat loss in humans | Phase IIb/III RCTs by Metabolic Pharmaceuticals (failed) | Negative: no significant fat loss vs placebo in pivotal trials | Low (against effect) |
| MOTS-c | Metabolic rate increase, fat oxidation | Animal studies; single small human trial (Lee et al., Cell Metab 2015 for mechanism) | Positive in rodents; human fat-loss data absent | Very Low |
| BPC-157 | Fat loss | Animal only; no human fat-loss data | Not applicable to fat loss | Very Low |
How Do Fat-Burning Peptides Actually Work? Mechanism with Numbers
Fat-burning peptides operate through two primary axes. Understanding which axis a peptide acts on tells you how strong the expected effect is.
Axis 1: GH secretagogue pathway. Peptides like CJC-1295 (a GHRH analogue) and ipamorelin (a ghrelin receptor agonist, also called GHS-R1a) stimulate pituitary GH release. GH activates hormone-sensitive lipase (HSL) in adipocytes via a cAMP-PKA cascade, promoting hydrolysis of stored triglycerides to free fatty acids. GH also suppresses lipoprotein lipase (LPL) activity in adipose tissue, reducing fat uptake. In the Teichman 2006 study, a single dose of CJC-1295 with DAC raised mean GH area under the curve by 2 to 10 fold depending on dose (0.03 to 0.3 mg/kg range). What that mechanism does NOT prove is that the resulting GH elevation is large enough or prolonged enough to produce clinically meaningful fat loss in an adult in caloric balance.
Axis 2: GLP-1 receptor agonist pathway. Semaglutide and liraglutide are GLP-1 peptide analogues. They bind the GLP-1 receptor (a class B GPCR), reducing appetite via hypothalamic signaling, slowing gastric emptying, and increasing insulin secretion in a glucose-dependent manner. The STEP 1 trial (Wilding et al., NEJM 2021, n=1,961) demonstrated a mean 14.9% body weight loss with 2.4 mg weekly subcutaneous semaglutide versus 2.4% placebo at 68 weeks. This is mechanistically and quantitatively distinct from the GH axis.
Axis 3: AOD-9604 (failed). AOD-9604 is the C-terminal fragment (residues 177 to 191) of human GH. It was designed to retain GH's lipolytic activity (thought to reside in that region) while avoiding the diabetogenic and growth-promoting effects of the full GH molecule. In rodent models, it did stimulate lipolysis. In humans, pivotal trials did not replicate the effect at tolerated doses. The failure illustrates that fragment activity in animals is not predictive of human efficacy.
The Top Fat-Burning Peptides Ranked by Evidence Quality
1. Semaglutide (Ozempic / Wegovy) -- Strongest Human Evidence
A 31-amino-acid GLP-1 analogue with a C18 fatty diacid chain that extends half-life to approximately 7 days, enabling once-weekly dosing. FDA-approved for obesity (Wegovy, 2.4 mg weekly) and type 2 diabetes (Ozempic). The STEP clinical program produced four large Phase III trials. Fat mass loss, not just weight, was confirmed by DEXA in multiple substudies. This is the category benchmark. Its limitation for this comparison: it is a regulated prescription drug, not a research compound.
2. Tesamorelin (Egrifta) -- Best for Visceral Fat, Narrow Approval
A 44-amino-acid synthetic GHRH analogue with a trans-3-hexenoic acid group at the N-terminus stabilizing it against dipeptidyl peptidase IV cleavage. FDA-approved 2010 for HIV lipodystrophy at 2 mg subcutaneous daily. Falutz et al. (NEJM 2007) reported roughly 15 to 18% reduction in visceral adipose tissue versus placebo at 26 weeks. Off-label use in healthy adults is not supported by equivalent RCT evidence, and visceral fat returned toward baseline after discontinuation in the trial extension data.
3. CJC-1295 with DAC plus Ipamorelin -- Most Common Research Combo, Low Evidence Ceiling
CJC-1295 with DAC is a GHRH analogue modified with a maleimide-based Drug Affinity Complex that covalently binds to albumin Cys-34, extending plasma half-life from under 30 minutes to roughly 6 to 8 days (Teichman et al., 2006). Ipamorelin is a pentapeptide GHS-R1a agonist that stimulates GH release with low cortisol and prolactin stimulation compared to earlier secretagogues like GHRP-6. Used together, they create additive GH stimulation via complementary receptor pathways. The honest ceiling: GH elevation from this combination has not been shown in a well-powered RCT to produce fat loss as a primary, measured endpoint in healthy adults without caloric restriction.
4. MOTS-c -- Interesting Mechanism, Very Early Human Data
A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. In rodent studies, it activates AMPK, increases insulin sensitivity, and promotes fat oxidation. Lee et al. (Cell Metabolism 2015) demonstrated the mechanism in mice. A small human pharmacokinetic study exists, but human fat-loss data as a primary endpoint is absent. Categorized here for completeness, not recommendation.
5. AOD-9604 -- Do Not Recommend Based on Failed Trials
Mechanistically interesting in animals. Failed Phase IIb/III. Metabolic Pharmaceuticals discontinued the obesity program. AOD-9604 was subsequently granted GRAS (Generally Recognized as Safe) status as a food ingredient in the US, but GRAS status says nothing about efficacy. Including it here specifically to prevent misinformation; many commodity pages still present it as effective.
What Most Pages Get Wrong About the Best Fat Burning Peptide
- Conflating GH elevation with fat loss. Raising GH is not the same as losing fat. GH has lipolytic effects, but those effects depend on dose, duration, baseline GH status, caloric intake, and receptor sensitivity. A two-fold GH increase from a secretagogue in a well-fed adult in their 30s does not automatically translate to measurable fat loss on a DEXA scan.
- Presenting AOD-9604 as effective. Animal lipolysis data in peptide marketing circulates long after the human trials failed. This is the clearest example of commodity-page misinformation in this category.
- Ignoring bioavailability by route. Orally administered peptides are almost entirely degraded by gastric proteases before reaching systemic circulation. Any "fat burning peptide" sold in capsule or tablet form relies on oral bioavailability that the peptide chemistry does not support unless specially formulated (cyclic, lipidated, or nanoparticle-encapsulated). The subcutaneous injection route is the validated delivery method for every peptide in the evidence ledger above.
The Chemistry Behind Storage and Stability Rules
Why cold storage matters. Peptide bonds are susceptible to hydrolysis, and the rate of that hydrolysis follows Arrhenius kinetics: roughly doubling for every 10 degree Celsius rise in temperature. In aqueous solution, asparagine-containing sequences (present in several GH-axis peptides) are particularly prone to deamidation, converting Asn to Asp and altering receptor binding. Lyophilized (freeze-dried) powder removes water, dramatically slowing both hydrolysis and oxidation. This is why the powder form is stable for months at 2 to 8 degrees Celsius, while reconstituted solution degrades meaningfully within weeks at the same temperature.
Why repeated freeze-thaw cycles degrade peptides. Ice crystal formation during freezing mechanically disrupts tertiary structure and can break disulfide bonds. Each freeze-thaw cycle introduces this stress. The practical solution is to aliquot reconstituted peptide into single-use volumes before freezing so that the primary stock is only thawed once.
Why bacteriostatic water, not sterile water. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) inhibits microbial growth over the multi-week use period. Sterile water has no preservative and increases contamination risk in multi-dose vials. Benzyl alcohol at 0.9% does not meaningfully degrade common research peptides at the concentrations used.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Compound | Evidence Level | Avg Fat Loss (Human) | Route | Regulated Status | Peptide Wins? |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg weekly | High (Phase III) | ~15% body weight at 68 wks | Subcut injection | FDA-approved Rx | This IS a peptide and the benchmark |
| Tesamorelin 2 mg/day | High (in approved pop.) | ~15-18% visceral fat at 26 wks | Subcut injection | FDA-approved Rx (narrow indication) | Yes, for visceral fat in lipodystrophy |
| CJC-1295/Ipamorelin combo | Low | Not established in RCT | Subcut injection | Research compound | No vs. approved alternatives |
| Orlistat 120 mg TID | High (Phase III) | ~3-4 kg more than placebo at 1 year | Oral | FDA-approved (OTC/Rx) | No; peptides not proven to exceed this |
| Phentermine/topiramate ER | High (Phase III) | ~9% body weight at 1 year | Oral | FDA-approved Rx (Qsymia) | No (research peptides) |
| AOD-9604 | Low (negative RCT) | Not significant vs. placebo | Subcut injection | Research compound / GRAS food ingredient | No |
The honest conclusion: if fat loss is the primary goal and you have access to a prescriber, FDA-approved GLP-1 agonists are categorically better-evidenced than any research-compound peptide. Research peptides like CJC-1295 and ipamorelin occupy a different use-case, typically optimization of body composition in individuals already at a healthy weight who want to preserve lean mass while in a caloric deficit, and even there the RCT evidence for that specific outcome is thin.
Operational and Label Literacy: How to Judge a Peptide Product
Reading a Certificate of Analysis (COA). A complete COA contains four elements:
- Identity (MS): Molecular weight by mass spectrometry must match the theoretical molecular weight of the peptide sequence. For ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2), the monoisotopic mass is approximately 711.4 Da. A COA citing only HPLC purity without MS identity cannot confirm you have the right molecule.
- Purity (HPLC): Reverse-phase HPLC purity above 98% is the research-grade standard. Values below 95% suggest significant impurities that could include bioactive degradation products.
- Endotoxin (LAL assay): Below 1 EU/mg for injectable research compounds. Endotoxin contamination from bacterial cell walls causes fever, inflammation, and in severe cases septic shock, entirely independent of the peptide itself.
- Moisture (Karl Fischer titration): Below 8% by weight. Excessive moisture in lyophilized powder indicates poor manufacturing and accelerates degradation during storage.
Reconstitution math example for CJC-1295 with DAC at 5 mg/vial. To make a 1 mg/mL solution: add 5 mL of bacteriostatic water to the vial. Each 0.1 mL drawn (a "10-unit" insulin syringe mark) delivers 0.1 mg. A common research protocol uses 1 to 2 mg twice weekly; at 1 mg/injection and 1 mg/mL concentration, that is 1 mL per injection. Check your math before every reconstitution change.
Dosing Reference Table (Research Context, Not Medical Advice)
| Peptide | Common Research Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| Tesamorelin | 2 mg (FDA-approved dose) | Once daily | Subcut | Approved indication only; glucose monitoring recommended |
| CJC-1295 with DAC | 1 to 2 mg | Once or twice weekly | Subcut | Long half-life; daily dosing is unnecessary and not supported by PK data |
| Ipamorelin | 200 to 300 mcg | 2 to 3 times daily | Subcut | Short half-life requires frequent dosing; often combined with CJC-1295 |
| Semaglutide (Wegovy) | 0.25 mg titrating to 2.4 mg | Once weekly | Subcut | Requires dose titration over 16 to 20 weeks; Rx only |
| AOD-9604 | Not recommended | N/A | N/A | Failed human trials; no evidence-based dose recommendation |
Frequently Asked Questions
What is the best fat burning peptide backed by human evidence?
Tesamorelin has the strongest human RCT evidence for fat reduction, specifically visceral adipose tissue in HIV-associated lipodystrophy. Semaglutide (a GLP-1 receptor agonist peptide) has the strongest evidence for general obesity. Among research compounds, CJC-1295 with DAC and ipamorelin have modest supportive human data but no large independent RCTs for fat loss specifically.
Does AOD-9604 actually burn fat in humans?
AOD-9604 failed its pivotal Phase IIb/III human weight-loss trials conducted by Metabolic Pharmaceuticals. The company discontinued its obesity program after those results. Animal lipolysis data does not translate to clinically meaningful human fat loss at doses studied.
How do growth hormone secretagogues reduce fat?
GH secretagogues raise pulsatile GH, which activates hormone-sensitive lipase via cAMP signaling, promoting free fatty acid release from adipocytes. GH also suppresses lipoprotein lipase in adipose tissue, reducing fat uptake. The net lipolytic effect is real but modest without caloric deficit.
What is the difference between CJC-1295 with DAC and without DAC for fat loss?
CJC-1295 with DAC binds albumin via a maleimide linker, extending half-life to roughly 6 to 8 days versus under 30 minutes for the unmodified peptide. The extended half-life produces a sustained GH elevation rather than a sharp pulse. Neither form has a large RCT demonstrating fat loss as a primary endpoint in healthy adults.
Is tesamorelin approved for fat loss?
Yes. The FDA approved tesamorelin (Egrifta) in 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for general obesity or cosmetic fat reduction.
Can peptides replace diet and exercise for fat loss?
No. Even the strongest peptide evidence, including GLP-1 agonist trials, shows greater fat loss when behavioral interventions accompany the drug. For research-grade peptides like ipamorelin or CJC-1295, there is no human trial demonstrating meaningful fat loss without an accompanying energy deficit.
What does a degraded or counterfeit fat-burning peptide look like?
Lyophilized peptides should be a white to off-white powder. Yellow, brown, or amber discoloration suggests oxidation or impurities. After reconstitution, clear solution is expected; cloudiness or particulates indicate degradation or contamination. A legitimate supplier provides a Certificate of Analysis from a third-party lab showing purity above 98% by HPLC.
How should fat-burning peptides be stored to prevent degradation?
Lyophilized peptides are stable at room temperature for short periods but should be stored at 2 to 8 degrees Celsius long-term. Once reconstituted, store at 2 to 8 degrees Celsius and use within 28 to 30 days. Repeated freeze-thaw cycles degrade peptide bonds; avoid them by aliquoting before freezing.
What peptide has the best evidence for visceral fat specifically?
Tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent versus placebo in two pivotal RCTs (Falutz et al., NEJM 2007 and a follow-up confirmatory study) in HIV lipodystrophy patients. No research-compound peptide has equivalent human visceral fat data.
Is ipamorelin safe for fat loss use?
Ipamorelin has a favorable safety profile in the human studies that exist, mainly small trials evaluating GI motility and postoperative ileus rather than fat loss. Long-term safety data specific to fat-loss protocols in healthy adults is absent. Potential risks include elevated fasting glucose and theoretical promotion of occult neoplasms via IGF-1 elevation.
How do I read a peptide Certificate of Analysis?
Key items: identity confirmed by mass spectrometry (molecular weight matches sequence), purity above 98% by reverse-phase HPLC, endotoxin below 1 EU/mg by LAL assay, and moisture content below 8% by Karl Fischer titration. A COA without MS confirmation of identity is incomplete regardless of HPLC purity.
Which fat-burning peptide is closest to an approved drug?
Semaglutide and liraglutide are GLP-1 receptor agonist peptides with full FDA approval for obesity (Wegovy, Saxenda). They are the only fat-burning peptides with large Phase III RCT data in general obesity populations, making them categorically stronger evidence than any research compound.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021; 384(11):989-1002.
- Falutz J et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. NEJM 2007; 357(23):2359-2370.
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab 2006; 91(3):799-805.
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015; 21(3):443-454.
- Metabolic Pharmaceuticals Ltd. AOD9604 Phase IIb/III clinical program results (corporate communications, 2007). Program discontinuation documented in peer literature and regulatory submissions.
- FDA. Egrifta (tesamorelin for injection) Prescribing Information. NDA 022505. Approved November 2010.
- FDA. Wegovy (semaglutide injection) Prescribing Information. NDA 215256. Approved June 2021.
- Kojima M et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660. (foundational GHS-R1a receptor biology)
- Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008; 149(9):601-611.
- USP General Chapter 1> Injections and Implanted Drug Products (Container-Closure Integrity Testing). United States Pharmacopeia.